Palisade Bio, Inc. (PALI)
NASDAQ: PALI · Real-Time Price · USD
1.700
+0.010 (0.59%)
Sep 17, 2026, 4:00 PM EDT - Market closed
Palisade Bio Revenue
Palisade Bio had revenue of $500.00K in the quarter ending June 30, 2026. This brings the company's revenue in the last twelve months to $500.00K.
Revenue (ttm)
$500.00K
Revenue Growth
n/a
P/S Ratio
592.52
Revenue / Employee
$35,714
Employees
14
Market Cap
296.26M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 250.00K | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Century Therapeutics | 109.16M |
| Enanta Pharmaceuticals | 65.26M |
| Fennec Pharmaceuticals | 59.22M |
| Q32 Bio | 53.74M |
| Orchestra BioMed Holdings | 31.98M |
| X4 Pharmaceuticals | 15.85M |
| Evommune | 10.00M |
| Ocugen | 4.58M |
PALI News
- 1 day ago - Palisade Bio Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 1 day ago - Palisade Bio Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 14 days ago - Palisade Bio to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 5 weeks ago - Palisade Bio reports Q2 EPS (22c), consensus (5c) - TheFly
- 5 weeks ago - Palisade Bio Quarterly report: Q2 2026 - Filings
- 5 weeks ago - Palisade Bio Earnings release: Q2 2026 - Filings
- 6 weeks ago - Palisade Bio Slides: Corporate presentation - Filings
- 1 month ago - Palisade Bio initiated with an Outperform at Oppenheimer - TheFly